Low-Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real-World Study in China.

Notably, the mid‐LVO subgroup exhibited numerically smaller reductions in resting and provoked gradients compared with LVOTO patients, with a clinically relevant difference trend that did not reach statistical significance likely due to MVO′s limited sample size, suggesting potentially diminished mavacamten efficacy in mid‐cavitary obstruction that warrants validation in larger cohorts.

also in 111,027 other papers